カテゴリ： GlobalData, アメリカ, 企業調査

Mersana Therapeutics Inc (MRSN)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Mersana Therapeutics Inc (MRSN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7591
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：61
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Mersana Therapeutics Inc (Mersana) formerly Nanopharma Corp is a clinical-stage biopharmaceutical company that offers antibody drug conjugate to improve patients’ lives. The company offers pipeline product XMT-1522, for HER-2 targeted therapies based on its Dolaflexin platform. It utilizes Fleximer antibody drug conjugation (ADC) platform, Dolaflexin to design ADC’s with drug-to-antibody ratios. Mersana’s Dolaflexin platform offers custom design of an ADC with specific properties to target a particular type of cancer. The company develops immunoconjugates to deliver payloads of anti tumor agents directly to cancerous cells. Its products are developed for multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.

Mersana Therapeutics Inc (MRSN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 12
Mersana Therapeutics Raises USD35 Million in Series B Financing 14
Mersana Therapeutics Secures USD14.51 Million in Venture Funding 15
Mersana Therapeutics Raises US$5 Million In Venture Financing 16
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 17
Mersana Therapeutics Raises Additional US$4 Million In Venture Financing 19
Partnerships 20
Mersana Therapeutics Expands Agreement with Takeda Pharma 20
Mersana Expands Co-Development Agreement with Takeda Pharma 21
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 22
Licensing Agreements 23
Mersana Therapeutics Enters into Licensing Agreement with Recepta Biopharma 23
Mersana Exercises Option for License Agreement with Millennium 24
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 25
Mersana Therapeutics Amends its Licensing Agreement with Adimab 26
Equity Offering 27
Mersana Therapeutics Plans to Raise up to USD250 in Public Offering of Securities 27
Mersana Therapeutics Raises USD75 Million in IPO 28
Mersana Therapeutics Inc – Key Competitors 30
Mersana Therapeutics Inc – Key Employees 31
Mersana Therapeutics Inc – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
Financial Announcements 33
Aug 14, 2018: Mersana Therapeutics reports second quarter 2018 financial results 33
May 14, 2018: Mersana Therapeutics Reports First Quarter 2018 Financial Results 35
Mar 28, 2018: Mersana Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results 36
Nov 09, 2017: Mersana Announces Third Quarter 2017 Financial Results and Provides Business Updates 38
Aug 11, 2017: Mersana Announces Second Quarter 2017 Financial Results and Provides Business Updates 40
Corporate Communications 42
Mar 19, 2018: Mersana Therapeutics Appoints Willard H. Dere As Board Director 42
Mar 12, 2018: Mersana Appoints David A. Spellman as Chief Financial Officer 43
Sep 05, 2017: Mersana Appoints Lawrence M. Alleva to Board of Directors 44
Jan 05, 2017: Mersana Therapeutics Appoints Andrew A. F. Hack, M.D., Ph. D. to Board of Directors 45
Product News 46
03/02/2017: Mersana Presents New Data on Investigational Cancer Antibody Drug Conjugate at American Association of Cancer Research Annual Meeting 46
Product Approvals 47
Sep 17, 2018: Mersana Therapeutics provides update on XMT-1536 47
Clinical Trials 48
Sep 25, 2018: Mersana Therapeutics presents new preclinical data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer 48
Jun 04, 2018: Mersana Presents Interim Dose-Escalation Data on XMT-1522 in Select Cancers at ASCO 2018 49
May 22, 2018: Mersana Therapeutics to Present Interim Phase 1 Data on XMT-1522 at the 2018 American Society of Clinical Oncology Annual Meeting 50
Apr 17, 2018: Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018 51
Apr 09, 2018: Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018 52
Dec 12, 2017: Mersana Announces First Patient Dosed with XMT-1536 in Phase 1 Study in Patients with NaPi2b-Expressing Tumors 53
Oct 30, 2017: Mersana Announces FDA Clearance of IND Application for XMT-1536, a First-in-Class Antibody Drug Conjugate Targeting NaPi2b 54
Oct 30, 2017: Mersana Therapeutics Presents New Data on XMT-1536, a NaPi2b Targeting Antibody Drug Conjugate, at the AACR-NCI-EORTC International Conference 55
Oct 23, 2017: Mersana Therapeutics Announces Poster Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 56
Jun 05, 2017: Mersana Confirms Clinical Trial Progress on Lead Oncology Program at ASCO 2017 57
Apr 02, 2017: Mersana Therapeutics Presents Preclinical Data on XMT-1522 Supporting Efficacy and Tolerability 58
Other Significant Developments 59
Jan 08, 2018: Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals 59
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mersana Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 12
Mersana Therapeutics Raises USD35 Million in Series B Financing 14
Mersana Therapeutics Secures USD14.51 Million in Venture Funding 15
Mersana Therapeutics Raises US$5 Million In Venture Financing 16
Mersana Therapeutics Raises US$27 Million In Series A-1 Financing 17
Mersana Therapeutics Raises Additional US$4 Million In Venture Financing 19
Mersana Therapeutics Expands Agreement with Takeda Pharma 20
Mersana Expands Co-Development Agreement with Takeda Pharma 21
Mersana Therapeutics Enters Into Co-Development Agreement With Endo Pharma 22
Mersana Therapeutics Enters into Licensing Agreement with Recepta Biopharma 23
Mersana Exercises Option for License Agreement with Millennium 24
EMD Serono Amends its Licensing Agreement with Mersana Therapeutics 25
Mersana Therapeutics Amends its Licensing Agreement with Adimab 26
Mersana Therapeutics Plans to Raise up to USD250 in Public Offering of Securities 27
Mersana Therapeutics Raises USD75 Million in IPO 28
Mersana Therapeutics Inc, Key Competitors 30
Mersana Therapeutics Inc, Key Employees 31

List of Figures
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mersana Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Mersana Therapeutics Inc (MRSN)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Lidco Group Plc (LID)：企業の製品パイプライン分析
    Summary Lidco Group Plc (LiDCO) is a medical device company that supplies hemodynamic monitoring equipment. The company's product portfolio include LiDCOrapid, LiDCOunity, LiDCOplus, LiDCOview and LiDCOaccessories . Its LiDCOplus is a computer-based platform monitor, which is used in the intensive c …
  • BioScrip Inc (BIOS)-医療機器分野：企業M&A・提携分析
    Summary BioScrip Inc (BioScrip), formerly MIM Corp is a healthcare service provider that offers infusion care services. The hospital provides a range of infusion services, PBM services and respiratory services. Its infusion therapy services include antimicrobial drugs, factor replacement therapy for …
  • Giant Eagle, Inc.：戦略・SWOT・企業財務分析
    Giant Eagle, Inc. - Strategy, SWOT and Corporate Finance Report Summary Giant Eagle, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • RKW SE：企業の戦略的SWOT分析
    RKW SE - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Vexim SA – Product Pipeline Analysis, 2018 Uate
    Summary Vexim SA (Vexim), a subsidiary of Stryker Corp, is a healthcare product manufacturer that provides solutions for patients suffering from vertebral compression fractures. The company provides solutions such as controlled anatomical restoration and advanced vertebroplasty therapy. Its controll …
  • Malee Group Public Company Limited：企業の戦略・SWOT・財務情報
    Malee Group Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Malee Group Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Achira Labs Pvt Ltd：企業の製品パイプライン分析2018
    Summary Achira Labs Pvt Ltd (Achira Labs) is an immunodiagnostics company that develops diagnostics solutions for developing countries. The company offers ACIX100, a microfluidics platform that combines a plastic disposable cartridge containing dry reagents and a desktop reader instrument. Its ACIX …
  • ZIOPHARM Oncology Inc (ZIOP)：企業の財務・戦略的SWOT分析
    Summary Ziopharm Oncology Inc (Ziopharm), is a provider of next-generation immune therapies. The company offers Controlled IL-12 and t-cell therapy to fight blood cancers and solid tumors. Its Controlled IL-12 platform provides therapy for cold tumors by turning them hot by activating an immune resp …
  • True Corporation Public Company Limited：企業の戦略・SWOT・財務情報
    True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary True Corporation Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Tzamal Medical Group Ltd：製薬・医療：M&Aディール及び事業提携情報
    Summary Tzamal Medical Group Ltd (Tzamal Medical) is a medical device company that manufactures and markets medical equipment, implants, disposables, surgical instruments and veterinary drugs. The company’s products include disposable products, patient monitor equipment and patient self testing equi …
  • Rehrig Pacific Company：企業の戦略的SWOT分析
    Rehrig Pacific Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • SandRidge Energy Inc (SD)：企業の財務・戦略的SWOT分析
    SandRidge Energy Inc (SD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Morneau Shepell Inc.：企業の戦略・SWOT・財務情報
    Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report Summary Morneau Shepell Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Epigenomics AG (ECX)：製薬・医療：M&Aディール及び事業提携情報
    Summary Epigenomics AG (Epigenomics) is a molecular diagnostics company which develops and commercializes in-vitro diagnostic (IVD) tests for screening, early detection and diagnosis of cancer. Its lead product, Epi proColon is a blood-based test for rapid detection of colorectal cancer; and Epi pro …
  • Avacta Group Plc (AVCT)：企業の財務・戦略的SWOT分析
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta’s sensipod is an …
  • The Tokyo Electric Power Company, Incorporated：企業の戦略・SWOT・財務情報
    The Tokyo Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report Summary The Tokyo Electric Power Company, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, ope …
  • University of Pittsburgh Medical Center：製薬・医療：M&Aディール及び事業提携情報
    Summary University of Pittsburgh Medical Center (UPMC) is a health care provider organization. It is a non-profit health care firm comprising a wide network of hospitals, clinics, and long-term care, rehabilitation and retirement facilities. The company offers several services such as commercial, me …
  • Castle Brands Inc.：企業の戦略・SWOT・財務情報
    Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report Summary Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Efore Oyj (EFO1V)：企業の財務・戦略的SWOT分析
    Efore Oyj (EFO1V) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Saladax Biomedical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Saladax Biomedical Inc (Saladax) is a medical equipment company that develops diagnostic tests. The company provides products such as My5-FU, MyPaclitaxel, MyImatinib and MyDocetaxel, among others. Its My5-FU measures and helps physicians to optimize a patient’s exposure to 5-fluorouracil, M …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆